SARS-CoV-2 and the Eye: Implications for the Retina Specialist from Human Coronavirus Outbreaks and Animal Models.
2019-nCoV
COVID-19
Coronavirus
SARS-CoV-2
animal models
conjunctivitis
eye
ophthalmology
retina
uveitis
Journal
Journal of vitreoretinal diseases
ISSN: 2474-1264
Titre abrégé: J Vitreoretin Dis
Pays: United States
ID NLM: 101700301
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
ppublish
Résumé
The current SARS-CoV-2 pandemic has escalated rapidly since December 2019. Understanding the ophthalmic manifestations in patients and animal models of the novel coronavirus may have implications for disease surveillance. Recognition of the potential for viral transmission through the tear film has ramification for protection of patients, physicians, and the public. Information from relevant published journal articles was surveyed using a computerized PubMed search and public health websites. We summarize current knowledge of ophthalmic manifestations of SARS-CoV-2 infection in patients and animal models, risk mitigation measures for patients and their providers, and implications for retina specialists. SARS-CoV-2 is efficiently transmitted among humans, and while the clinical course is mild in the majority of infected patients, severe complications including pneumonia, acute respiratory distress syndrome, and death can ensue, most often in elderly patients and individuals with co-morbidities. Conjunctivitis occurs in a small minority of patients with COVID-19 and SARS-CoV-2 RNA has been identified primarily in association with conjunctivitis. Uveitis has been observed in animal models of coronavirus infection and cotton-wool spots have been reported recently. SARS-CoV-2 and other coronaviruses have been rarely associated with conjunctivitis. The identification of SARS-CoV and SARS-CoV-2 RNA in the tear film of patients and its highly efficient transmission via respiratory aerosols supports eye protection, mask and gloves as part of infection prevention and control recommendations for retina providers. Disease surveillance during the COVID-19 pandemic outbreak may also include ongoing evaluation for uveitis and retinal disease given prior findings observed in animal models and a recent report of retinal manifestations.
Identifiants
pubmed: 33665540
doi: 10.1177/2474126420939723
pmc: PMC7928265
mid: NIHMS1611056
doi:
Types de publication
Journal Article
Langues
eng
Pagination
411-419Subventions
Organisme : NIAID NIH HHS
ID : R38 AI140299
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029594
Pays : United States
Organisme : NEI NIH HHS
ID : K23 EY030158
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY006360
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG062334
Pays : United States
Références
Emerg Infect Dis. 2005 Aug;11(8):1225-9
pubmed: 16102311
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
Virology. 1991 Feb;180(2):567-82
pubmed: 1846489
Invest Ophthalmol Vis Sci. 1992 Jan;33(1):60-7
pubmed: 1309730
J Immunol. 1993 Sep 15;151(6):3381-9
pubmed: 8397257
Br J Ophthalmol. 2004 Jul;88(7):861-3
pubmed: 15205225
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Heliyon. 2021 Jan;7(1):e05850
pubmed: 33392409
N Engl J Med. 2014 Jun 26;370(26):2499-505
pubmed: 24896817
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
J Virol. 2010 Apr;84(7):3134-46
pubmed: 19906932
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Vet Ophthalmol. 2013 Jul;16 Suppl 1:160-3
pubmed: 23607772
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Invest Ophthalmol Vis Sci. 1996 Jan;37(1):250-4
pubmed: 8550331
Ophthalmology. 2020 Jul;127(7):977-979
pubmed: 32291098
J Infect Dis. 2018 Nov 22;218(suppl_5):S423-S433
pubmed: 30053050
J Infect Dis. 2007 Nov 15;196 Suppl 2:S323-8
pubmed: 17940967
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Comp Pathol. 2015 Feb-Apr;152(2-3):265-8
pubmed: 25678422
Lancet. 2020 May 23;395(10237):1610
pubmed: 32405105
Br J Ophthalmol. 2004 Jul;88(7):968-9
pubmed: 15205249
Lancet Infect Dis. 2014 Feb;14(2):140-5
pubmed: 24355866
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Med Virol. 2020 Jun;92(6):589-594
pubmed: 32100876
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 Apr 2;382(14):1370-1371
pubmed: 32163697
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
J Hosp Infect. 2017 Feb;95(2):207-213
pubmed: 28153558
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Ocul Surf. 2020 Jul;18(3):360-362
pubmed: 32289466
Proc Natl Acad Sci U S A. 1967 Apr;57(4):933-40
pubmed: 5231356
Vet Pathol. 2017 Nov;54(6):933-944
pubmed: 29065819
Wei Sheng Yan Jiu. 2005 Jul;34(4):412-5
pubmed: 16229261
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Open Virol J. 2010 May 25;4:76-84
pubmed: 20700397
Respirology. 2018 Feb;23(2):130-137
pubmed: 29052924
Virology. 1996 Aug 15;222(2):446-50
pubmed: 8806529
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Viruses. 2019 Oct 24;11(11):
pubmed: 31652964
Zhonghua Liu Xing Bing Xue Za Zhi. 2003 May;24(5):347-9
pubmed: 12820924
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Viruses. 2019 Jan 09;11(1):
pubmed: 30634396
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Viruses. 2019 Jan 14;11(1):
pubmed: 30646565
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
Ann Intern Med. 2020 Aug 4;173(3):242-243
pubmed: 32302380
Proc Soc Exp Biol Med. 1966 Jan;121(1):190-3
pubmed: 4285768
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lab Invest. 1990 Apr;62(4):417-26
pubmed: 2159082